Defendant Name: Mead Johnson Nutrition Company

Defendant Type: Public Company
SIC Code: 2023
CUSIP: 58283910

Document Reference: 34-75532

Document Details

Legal Case Name In the Matter of Mead Johnson Nutrition Company
Document Name Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings and Imposing a Cease-and-Desist Order
Document Date 28-Jul-2015
Document Format Administrative Proceeding
File Number 3-16704
Allegation Type Foreign Corrupt Practices Act
Document Summary On July 28, 2015, without admitting or denying the SEC's allegation, Mead Johnson Nutrition Company ("Mead Johnson" or "Respondent") consented to the entry of the Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order ("Order"). According to the Order, the matter "concerns violations of the books and records and internal controls provisions of the Foreign Corrupt Practices Act ('FCPA') by Mead Johnson," which occurred in connection with the operations of Mead Johnson's subsidiary in China ("Mean Johnson China") and took place up through 2013. Further, "Mead Johnson China's books and records were consolidated into Mead Johnson's books and records, thereby causing Mead Johnson's consolidated books and records to be inaccurate."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:

Disgorgement

Individual:     $7,770,000.00 Shared:    

Civil Penalty

Individual:     $3,000,000.00 Shared:    

Pre-Judgment Interest

Individual:     $1,260,000.00 Shared:    

Total Penalty

Individual:     $12,030,000.00 Shared:    

Related Documents:

2015-154 28-Jul-2015 Press Release--Administrative Proceeding
SEC Charges Mead Johnson Nutrition with FCPA Violations
On July 28, 2015, the SEC announced that Mead Johnson Nutrition Company agreed to settle charges under the Foreign Corrupt Practices Act that its Chinese subsidiary made improper payments in China, "to health care professionals at government-owned hospitals to recommend the company's infant formula to patients who were new or expectant mothers." The SEC alleged that Mead Johnson, "did not accurately reflect in its books and records the more than $2 million in improper payments made during a five-year period."